News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck & Co., Inc. (MRK) Announces Completion of NovaCardia, Inc. Acquisition


9/11/2007 10:09:39 AM

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. today announced that it has successfully completed the acquisition of NovaCardia, Inc., a privately held clinical-stage pharmaceutical company focused on cardiovascular disease. This acquisition adds rolofylline (KW-3902), NovaCardia's investigational Phase III compound for acute heart failure to Merck's pipeline.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES